NDAORALTABLET
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
Adrenergic alpha-Antagonists
Pharmacologic Class:
alpha-Adrenergic Blocker
Indications (13)
mild-to-severe chronic heart failure of ischemiccardiomyopathic originusually in addition to diureticsACE inhibitorsdigitalisto increase survival andalsoto reduce the risk of hospitalization [seeessential hypertension [seecardiovascular mortality in clinically stable patientsequal to 40% (withheart failurehypertension
Clinical Trials (5)
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Started Jul 2025
25 enrolled
Cancer
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Started May 2025
580 enrolled
Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Started Aug 2024
27 enrolled
Urologic NeoplasmsUrogenital NeoplasmsMale Urogenital Diseases+3 more
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Started May 2024
90 enrolled
Melanoma Stage IIIMelanoma Stage IVAdvanced Melanoma+1 more
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Started Jan 2024
0Squamous Cell Carcinoma of Head and NeckLocally Advanced Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma